

in . bio . motion



A new era in  
personalized  
breast cancer  
care

● **The MAF Test<sup>®</sup>**

by Inbiomotion



# What is the MAF Test®?

The MAF Test® by Inbiomotion is an advanced diagnostic tool designed to enhance treatment decisions in early-stage breast cancer. By detecting MAF gene amplification, the test provides oncologists with critical insights into a patient's risk of developing bone metastasis and relapse. This information is vital for identifying patients who may benefit from bisphosphonate therapy, such as zoledronic acid or clodronate, allowing for more precise and effective treatment plans.

MAF gene status plays a pivotal role in guiding bisphosphonate therapy. Studies have shown that MAF-negative patients are likely to benefit from bisphosphonates, experiencing a reduced risk of bone metastasis and improved outcomes.<sup>3,4,5</sup> On the other hand, MAF-positive patients may not benefit from bisphosphonates and, in some cases, could even be harmed by such treatment.<sup>3</sup> Therefore, identifying MAF status through the MAF Test® is essential for ensuring that the right patients receive the appropriate therapy, optimizing the benefit-risk ratio.<sup>6</sup>

Traditional breast cancer treatment guidelines often consider imprecise factors like menopausal status for patient stratification.<sup>1,2</sup> However, these factors, while of some use, may not always capture the full complexity of an individual patient's cancer. In sharp contrast, the MAF Test® offers a more precise, opt in/out biomarker-driven approach<sup>6</sup>, empowering oncologists to make decisions based on the specific biological characteristics of the cancer.

perspective from knowledge

**This advancement not only aligns with current ESMO/ASCO guidelines<sup>1,2</sup> but also enhances them, leading to improved patient outcomes.**

**🔴 Precise Stratification**

Accurately identifies patients at higher risk of metastasis in bone, relapse and death.<sup>3,4,5</sup>

**🔴 Clinical Impact**

Helps optimize the use of bisphosphonates<sup>6</sup>, leading to better patient outcomes.

**🔴 Biomarker-Driven Insights**

Moves beyond traditional stratification methods, offering a personalized approach to treatment.<sup>6</sup>



## Why choose the MAF Test®?

The MAF Test® is at the forefront of precise medicine in breast cancer care, offering several key benefits<sup>6</sup> for both oncologists and patients:

### 1. Enhanced Treatment Precision

The MAF Test® enables oncologists to tailor treatment strategies to the individual needs of each patient. The MAF Test® identifies those at higher risk of bone metastasis, and in addition, the test guides the selective use of bisphosphonates, ensuring that the right patients receive the most appropriate therapy.

### 2. Improved Patient Outcomes

By providing actionable insights into metastasis risk, the MAF Test® supports the delivery of more targeted and effective treatment. This can lead to a reduction in the incidence of bone metastasis and overall better outcomes for patients.

### 3. Alignment with Clinical Guidelines

The MAF Test® not only complements current clinical guidelines but also provides additional layers of precision. This allows oncologists to go beyond standard stratification criteria, and independent of any clinicopathological variable, including postmenopausal status, to make accurate informed treatment decisions.

### 4. Evidence-Based Innovation

Rooted in rigorous scientific research, the MAF Test® represents the next generation of diagnostic tools in oncology. It reflects the latest advancements in cancer biology and offers a proven method for improving the personalization of breast cancer treatment.


The MAF Test® by Inbiomotion is a critical tool for any oncologist looking to elevate their approach to breast cancer treatment. By integrating cutting-edge science with clinical practice, it offers the potential to significantly improve patient care and outcomes.

1. Eisen et al., J Clin Oncol 40:787-800 (2022)  
2. Coleman et al, Annal Oncol. (31), 1650-1663 (2020)  
3. Coleman, R., Lancet Oncol 18(11): p. 1543-1552 (2017)  
4. Coleman et al, Journal of Bone Oncology 13 (2018)  
5. Paterson, A., JNCI Cancer Spectrum (2021)  
6. Coleman R.E., Journal of Bone and Mineral Metabolism 41:290-300 (2023)




## Transforming Oncology with the MAF Test®

The future of oncology lies in precision medicine, where treatments are tailored to the unique characteristics of each patient's cancer. The MAF Test® embodies this future, offering oncologists a powerful tool to enhance decision-making and optimize patient care. By incorporating the MAF Test® into your practice, you can ensure that your patients receive the most advanced and personalized treatment available.




## Discover the MAF Test®

Learn more about how the MAF Test® can transform your approach to breast cancer care. Contact us today to explore the possibilities of integrating this innovative test into your clinical practice.



**+34 935 17 35 45**

Copyright - All Rights Reserved



**perspective from knowledge**